Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.830
+0.020 (1.10%)
At close: Jul 25, 2025, 4:00 PM
1.840
+0.010 (0.54%)
After-hours: Jul 25, 2025, 7:29 PM EDT

Company Description

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.

It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair.

Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.

Biomea Fusion, Inc.
Biomea Fusion logo
CountryUnited States
Founded2017
IPO DateApr 16, 2021
IndustryBiotechnology
SectorHealthcare
Employees106
CEOMichael J. Hitchcock

Contact Details

Address:
1599 Industrial Road
San Carlos, California 94070
United States
Phone650 980 9099
Websitebiomeafusion.com

Stock Details

Ticker SymbolBMEA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001840439
CUSIP Number09077A106
ISIN NumberUS09077A1060
SIC Code2834

Key Executives

NamePosition
Dr. Michael J. M. Hitchcock Ph.D.Interim Chief Executive Officer and Director
Ramses M. ErdtmannCo-Founder, President, Chief Operating Officer and Director
Heow TanChief Technology and Quality Officer
Naomi CretcherChief People Officer
Dr. Thorsten Kirschberg Ph.D.Executive Vice President of Chemistry
Dr. Stephan Morris M.D.Chief Development Officer
Ravi Upasani Ph.D.Executive Vice President of Intellectual Property
Dr. Juan Pablo Frias M.D.Chief Medical Officer
Caroline Perez- Dupont J.D.Senior Vice President of Contracts

Latest SEC Filings

DateTypeTitle
Jul 24, 20258-KCurrent Report
Jul 22, 2025SCHEDULE 13D/AFiling
Jul 16, 2025SCHEDULE 13G/AFiling
Jun 25, 2025SCHEDULE 13GFiling
Jun 20, 20258-KCurrent Report
Jun 18, 20258-KCurrent Report
Jun 18, 2025424B5Filing
Jun 17, 2025424B5Filing
Jun 17, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report